Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Tom Hua who wrote (1240)	4/28/1998 12:56:00 AM
From: john david martin	Read Replies (4) \| Respond to of 25711

IFLYW should do a double tomorrow with the strong buy recommendation after market closed today. The warrant is now tethered to common a can't miss oppurtunity.

To: Tom Hua who wrote (1240)	4/28/1998 2:48:00 PM
From: Joe Copia	Respond to of 25711

CMPD news. In article it states it has the worldwide rights back from Merck !! biz.yahoo.com CompuMed, Inc. (Nasdaq: CMPD - news) announced today a breakthrough that will allow its proven OsteoGram bone density test to be performed using low-cost commercially available desktop scanners, as well as a wide variety of other digital inputs, such as digital x-ray machines and hospital and university teleradiology systems. The breakthrough technology builds upon the OsteoGram software originally developed by CompuMed and licensed to Merck & Co., Inc. (NYSE: MRK - news). Effective March 31, 1998, CompuMed regained the worldwide exclusive rights to the OsteoGram from Merck. more inside article Joe PTG&LI !!!